Amorfix's Misfolded SOD1 Therapeutic Programs at the Forefront of Major ALS Disease Discovery

TSX: AMF

TORONTO, Sept. 26, 2011 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that its Chief Scientific Officer and Director, Dr. Neil Cashman, and his team of researchers at the University of British Columbia and University of Alberta have published a ground breaking scientific paper in the Proceedings of the National Academy of Sciences (PNAS).  This paper demonstrates that superoxide dismutase 1 (SOD1), an important molecule in the pathogenesis of ALS, participates in a process called template-directed misfolding.  This is the first major publication describing the process by which misfolded SOD1 induces neighbouring SOD1 molecules to change shape and aggregate into large complexes in a fashion similar to the process underlying other misfolded proteins diseases such as Alzheimer's disease and may provide a molecular explanation for the for the onset and progression of ALS.

"These findings add great scientific support to both our therapeutic antibody and vaccine programs designed to neutralize misfolded SOD1 and halt the progression of disease" said Dr. Robert Gundel, Amorfix President and Chief Executive Officer.  "These programs are currently in preclinical development with our partners Biogen Idec (therapeutic antibodies) and PREVENT (vaccine) in the hope of advancing to clinical trials as quickly as possible."

About ALS

Amyotrophic lateral sclerosis, ALS or Lou Gerhig's disease, is a fatal neurodegenerative disease. People living with the disease become progressively paralyzed due to degeneration of the upper and lower motor neurons in the brain and spinal cord. Eighty per cent of people with ALS die within two to five years of diagnosis; unable to breathe or swallow. Ten per cent of those affected may live for 10 years or longer.

About Amorfix
www.amorfix.com

Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

SOURCE Amorfix Life Sciences Ltd.

For further information:

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
bob.gundel@amorfix.com
Janet Clennett
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899
Janet.clennett@amorfix.com

 

Profil de l'entreprise

Amorfix Life Sciences Ltd.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.